Robinetin Modulates TGF-β/ERK Signaling and Tumor-Associated Phenotype in 3D Osteosarcoma Spheroids
- 21 July 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 12 (8) , 4478-4492
Abstract
Osteosarcoma (OS) is the most frequent primary bone malignancy, with stagnant therapeutic progress. The current chemotherapy treatment shows limited efficacy in disseminating metastasis, and its recurrent use is associated with high systemic toxicity. Moreover, the absence of effective therapeutic strategies along with low complexity models for drug screen analysis hinders therapeutic progress. Herein, by developing a three-dimensional (3D) OS model, we found that compared to two-dimensional (2D) OS culture, the 3D spheroid model exhibited upregulation of pro-tumorigenic genes (IL6, OPN, and MMP2), as well as 3D-exclusive activation of TGF-β1 and p-ERK1/2. Additionally, we report the anticancer potential of robinetin, which successfully suppressed pro-tumorigenic genes and downregulated TGF-β1 and p-ERK1/2, demonstrating antitumor efficacy at a similar magnitude as doxorubicin while exhibiting low toxicity toward a healthy mesenchymal 3D system. In a scaffold-based 3D model with bone-mimicking stiffness, robinetin treatment suppressed pro-tumorigenic genes related to tumor invasiveness (FN1, OPN, IL6, and MMP2) and decreased the viability of OS cells upon exposure to TGF-β1. This study highlights robinetin as a promising candidate for selective OS therapy while emphasizing the reliability of advanced 3D OS models for anticancer drug screening and translational research.Keywords
Funding Information
- Fulbright Association (24-056)
- Fundação Luso-Americana para o Desenvolvimento (2025/0012)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR074234)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR077132)
- Laboratório Associado para a Química Verde (UID/50006)
- National NanoFab Center (RS-2024-00440903)
- Fundação para a Ciência e a Tecnologia (UI/BD/153618/2022)
This publication has 59 references indexed in Scilit:
- Three-dimensional preclinical models for Osteosarcoma: Advances and translational prospectsBiomedicine & Pharmacotherapy, 2025
- Three-dimensional cell spheroid culture and cell viability study of uveal melanoma cell line C918 with luteolin treatmentInternational Ophthalmology, 2024
- A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applicationsBiomaterials, 2023
- The role of flavonoids in the regulation of epithelial‐mesenchymal transition in cancer: A review on targeting signaling pathways and metastasisMedicinal Research Reviews, 2023
- Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro modelsIn vitro models, 2022
- Three‐Dimensional Osteosarcoma Models for Advancing Drug Discovery and DevelopmentAdvanced Therapeutics, 2018
- Structural analysis of photocrosslinkable methacryloyl-modified protein derivativesBiomaterials, 2017
- Regulation of osteosarcoma cell invasion through osteopontin modification by miR-4262Tumor Biology, 2015
- Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinationsBiomaterials, 2014
- TGF-β in cancer and bone: Implications for treatment of bone metastasesBone, 2011